Tanzania
Research Article
Chromium Therapy for Insulin Resistance Associated with HIV-Disease
Author(s): Seth A Stein, Margaret Mc Nurlan, Brett T Phillips, Catherine Messina, Dennis Mynarcik and Marie GelatoSeth A Stein, Margaret Mc Nurlan, Brett T Phillips, Catherine Messina, Dennis Mynarcik and Marie Gelato
Objective. With the advent of highly active anti-retroviral therapy, HIV disease has become a chronic condition, but with a number of metabolic complications including insulin resistance and diabetes mellitus, dyslipidemia and hypertension and an increased incidence of atherosclerosis. The aim of the current study was to test the safety and efficacy of chromium picolinate for HIV- associated insulin resistance. Materials/Methods: The study was a randomized, double-blind, placebo-controlled trial with subjects receiving 500μg of chromium picolinate or placebo twice daily for two months. HIV- infected subjects were selected based on a fasting concentration of plasma glucose greater than 5.5mmol/L or a plasma glucose concentration of greater than 7.7mmol/L (but less than 11mmol/L) 2h after oral ingestion of 75g of glucose. Insulin sensitivity was assessed with a hyper-insulinemic-eugl.. Read More»
DOI:
10.4172/2155-6113.1000239
Journal of AIDS & Clinical Research received 5264 citations as per Google Scholar report